Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Sep 03, 2024 1:59am
564 Views
Post# 36205634

What is Replicel really worth?

What is Replicel really worth?Now that this current AS takeover bid has made the rounds the question becomes what is the company in it's current state worth ?
 According to this takeover he is pegging the value as virtually worthless.  By not offering a traditional buyout even for $.10 per share which amounts to approx. $6,500,000 he is offering nothing with the promise to share 8% of any  potential profits in the future.

 He is saying the current development of the dermal injector which we were lead to believe was virtually ready to be submitted for FDA approval is worth nothing.  We were told this device would change the entire injection process in many dermal categories as well as the injection of stem cells.

RCH-01 had gone through at least 3 trials including Shiseido's trial with modest but encouraging results.  This is worth nothing ?

Numerous Patents covering the dermal injector as well as RCH-01, RCT-01, RCS-01.  Are they worth nothing ?

I am surpirsied that some Biotech or pharmaceutical companies that have followed Replicel over the years have not come out of the woodwork and made and offer.  Even Shiseido could find value in these assets.

What is the company really worth on the open market ?



<< Previous
Bullboard Posts
Next >>